SG11201506413PA - Sequestrants of advanced glycation end product (age) precursors - Google Patents

Sequestrants of advanced glycation end product (age) precursors

Info

Publication number
SG11201506413PA
SG11201506413PA SG11201506413PA SG11201506413PA SG11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA SG 11201506413P A SG11201506413P A SG 11201506413PA
Authority
SG
Singapore
Prior art keywords
sequestrants
precursors
age
end product
advanced glycation
Prior art date
Application number
SG11201506413PA
Other languages
English (en)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201506413PA publication Critical patent/SG11201506413PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201506413PA 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors SG11201506413PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
SG11201506413PA true SG11201506413PA (en) 2015-09-29

Family

ID=50439508

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506413PA SG11201506413PA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors
SG10201707590XA SG10201707590XA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201707590XA SG10201707590XA (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Country Status (24)

Country Link
US (2) US20160024233A1 (de)
EP (1) EP2968403A1 (de)
JP (4) JP2016512830A (de)
KR (1) KR20150130492A (de)
CN (1) CN105188718A (de)
AR (1) AR095593A1 (de)
AU (2) AU2014235500A1 (de)
BR (1) BR112015023404A8 (de)
CA (1) CA2906501A1 (de)
CL (1) CL2015002624A1 (de)
CR (1) CR20150545A (de)
DO (1) DOP2015000221A (de)
EA (1) EA201591733A1 (de)
HK (1) HK1220607A1 (de)
IL (1) IL241406A0 (de)
MA (1) MA38487A1 (de)
MX (1) MX2015012843A (de)
PE (1) PE20151766A1 (de)
PH (1) PH12015502019A1 (de)
SG (2) SG11201506413PA (de)
TN (1) TN2015000390A1 (de)
TW (1) TW201521744A (de)
UY (1) UY35441A (de)
WO (1) WO2014150873A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112020003638A2 (pt) * 2017-08-31 2020-09-01 Cytosorbents Corporation redução de produtos finais de glicação avançada a partir de fluidos corporais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
PT1923064T (pt) * 2001-04-18 2017-08-23 Genzyme Corp Utilização de um aminopolímero para reduzir a glicose sérica
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
EP1753861A4 (de) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc Fructosamin-3-kinase und die bildung von kollagen und elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
CN105017481B (zh) * 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺

Also Published As

Publication number Publication date
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
CL2015002624A1 (es) 2016-03-11
US20180265613A1 (en) 2018-09-20
AR095593A1 (es) 2015-10-28
SG10201707590XA (en) 2017-11-29
UY35441A (es) 2014-10-31
JP2016512830A (ja) 2016-05-09
KR20150130492A (ko) 2015-11-23
IL241406A0 (en) 2015-11-30
US20160024233A1 (en) 2016-01-28
MA38487A1 (fr) 2017-12-29
MX2015012843A (es) 2016-08-08
EA201591733A1 (ru) 2016-01-29
EP2968403A1 (de) 2016-01-20
JP2020055850A (ja) 2020-04-09
HK1220607A1 (zh) 2017-05-12
JP2022037143A (ja) 2022-03-08
BR112015023404A2 (pt) 2017-07-18
CA2906501A1 (en) 2014-09-25
CR20150545A (es) 2015-12-01
WO2014150873A1 (en) 2014-09-25
AU2019201259A1 (en) 2019-03-14
PE20151766A1 (es) 2015-12-11
TW201521744A (zh) 2015-06-16
PH12015502019A1 (en) 2016-01-11
DOP2015000221A (es) 2015-12-15
AU2014235500A1 (en) 2015-11-05
BR112015023404A8 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
GB201317887D0 (en) Product
GB201312991D0 (en) Process
SG11201508447TA (en) Expression process
HK1220983A1 (zh) 方法
GB201307334D0 (en) Process
GB2511521B (en) Product presenter
GB2512902B (en) Oligomerisation Process
GB201316269D0 (en) Process
GB201313915D0 (en) Process
GB201312729D0 (en) Cleaning product
GB2512903B (en) Oligomerisation Process
GB201314334D0 (en) Process
GB201302290D0 (en) Cleaning product
GB201307327D0 (en) Process
GB201302441D0 (en) Process
HK1220607A1 (zh) 晚期糖化終產物 前體的螯合劑
GB201415000D0 (en) Improved process
GB201311769D0 (en) Product
GB201307951D0 (en) Process
GB201300073D0 (en) Process
GB2518955B (en) Comestible product
GB201316253D0 (en) Process
GB201314561D0 (en) Process
GB201311837D0 (en) Expression Process
GB201306308D0 (en) Novel process